Clinical trials: Asthma
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Asthma
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the…
- Trial name
- UNIK (NCT01167010)
- Testing
- Formoterol/Budesonide, Foraseq, Alenia
- Where
- 5 sites in Brazil
- Volunteers
- 552 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Asthma
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12…
- Trial name
- CHASE 3 (NCT02091986)
- Testing
- Symbicort pMDI, Budesonide pMDI
- Where
- 70 sites in United States, Mexico and 2 more
- Volunteers
- 882 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma.
- Trial name
- NCT00392288
- Testing
- Ciclesonide
- Where
- 6 sites in United States, Hungary and 4 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Asthma
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years.
- Trial name
- BLANC (NCT04848662)
- Testing
- BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Bond Avillion 2 Development LP
Asthma
Study of Mepolizumab Autoinjector in Asthmatics
This study is aimed to assess the correct real-world use of an autoinjector for the repeat self-administration of mepolizumab SC, so to improve subject / physician convenience and to enable repeat dose self injection themselves…
- Trial name
- NCT03099096
- Testing
- Mepolizumab
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 159 people
- Sponsor
- GlaxoSmithKline
Asthma
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once…
- Trial name
- NCT01134042
- Testing
- Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder
- Where
- 71 sites in United States, Germany and 4 more
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks.
- Trial name
- NCT00442351
- Testing
- Asmanex twisthaler
- Volunteers
- 26 people
- Sponsor
- Organon and Co
Asthma
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
- Trial name
- NCT00812929
- Testing
- GSK2190915
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Acute Bronchial Obstruction, Asthma
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide plus Fenoterol in cumulative sequential doses in asthmatic children (5-<12 years) with acute bronchial obstruction attending emergency…
- Trial name
- NCT00460577
- Testing
- Formoterol fumerate, fenoterol/ipratropium bromide
- Where
- 2 sites in Venezuela
- Volunteers
- 60 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety Study in Subjects With Asthma
The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects…
- Trial name
- NCT00980200
- Testing
- Dose 4 QD, Dose 3 QD, Dose 2 QD
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Asthma
Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia
The purpose of the study is to evaluate the satisfaction level of patients using the Symbicort SMART approach for their asthma management.
- Trial name
- SMARTER (NCT00576316)
- Testing
- Symbicort Turbuhaler 160/4.5
- Where
- Malaysia
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Persistent Allergic Asthma
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood…
- Trial name
- NCT00870584
- Testing
- Omalizumab
- Where
- 50 sites in United States
- Volunteers
- 271 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate…
- Trial name
- NCT01706198
- Testing
- fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
- Where
- 180 sites in United Kingdom
- Volunteers
- 4,233 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with…
- Trial name
- NCT01244984
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 30 sites in Japan
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline